- Opinion
- [Reporter's View] Activation of the Generic Substitution
- by Kim, Jung-Ju Jan 14, 2021 01:23pm
- At the beginning of the year, small shops and large companies make actionable plans for the next year. The government plans the budget as well. In addition, the government divides and executes policy projects more detailed and strategically because administrative procedures and processes are more demanding than private enterprises. Accord
- Opinion
- [Reproter's View] Have you forgotten what the MFDS does?
- by Lee, Tak-Sun Jan 8, 2021 06:21am
- It was expected that the politics and media would put pressure on the introduction of COVID-19 vaccine, but it is too blatant. They only emphasize rapid introduction forgetting the role of the MFDS in verifying the safety and effectiveness of vaccines. From the time President Trump pressed the US FDA, the independence of the MFDS was ex
- Opinion
- [Reporter's View] Pharmaceutical dept. needs independence
- by Lee, Hye-Kyung Dec 18, 2020 06:06am
- The 'Rules on the Standards for National Health Insurance Medical Care Benefits' revised and implemented by the MOHW on October 8 became the basis for negotiating all reimbursed drugs with the NHIS. At the time, the pharmaceutical industry could not realize the 'power' of the rule amendment, but the NHIS emphasized that all drugs that nee
- Opinion
- [Contribution]Which is the first among COVID tx & vaccine?
- by Kang, Shin-Kook Dec 16, 2020 06:14am
- As vaccination has begun in foreign countries and the approval of antibody treatments in Korea is imminent, the need to establish strategies for quarantine is urgently emerging. Will the vaccination aim for population immunity, or will it aim for the effect of preventing severe disease and preventing spread by administering early treatment a
- Opinion
- [Reporter’s View] Notes on seeking for COVID-19 vaccine
- by An, Kyung-Jin Dec 14, 2020 05:59am
- The novel coronavirus disease-19 (COVID-19) is spreading at a concerning rate in South Korea. Although the social distancing level was raised to 2.5 two weeks after the government ordered the social distancing level 2 on Nov. 24, the third wave of pandemic seems to keep rising. The authority is even considering on raising the level up to 3,
- Opinion
- [Reporter’s View] Real reasons for disqualification?
- by Eo, Yun-Ho Dec 11, 2020 06:15am
- A multinational pharmaceutical company Sanofi Korea has failed to qualify as a certified innovative pharmaceutical company. Fairness aside, the transparency in the process seems questionable. Since its first certification won in 2014, the company lost its certification status after six years. Now, only three multinational companies&8212
- Opinion
- [Reporter’s View] Haste makes waste
- by Dec 4, 2020 05:55am
- The commercialization of the COVID-19 vaccine is approaching. The UK has already announced that the Pfizer vaccine will be approved for emergency use for the first time in the world and will be supplied early next week. Excluding vaccines from Russia and China that are not internationally recognized, this is the fastest action. The British go
- Opinion
- [Reporter's View]Drugs fluctuating prices should be excluded
- by Lee, Hye-Kyung Nov 24, 2020 09:01am
- The lawsuit for canceling eye drops’ price ended with the Supreme Court's ruling. Recently, the Supreme Court did not accept the appeal of 20 pharmaceutical companies, including Kookje, filed against the government to cancel a lawsuit for canceling the disposition of lowering the upper limit on the reimbursement of eye drops. After the defea
- Opinion
- [Reporter’s View] The sluggish shift in stepped pricing
- by Eo, Yun-Ho Nov 18, 2020 06:34am
- In June, South Korea’s Ministry of Health and Welfare (MOHW) issued an administrative notice to withdraw the plan to apply the stepped drug pricing reduction on drugs transferred by business restructuring. And it has been three months since the ministry completed collecting the public opinion in August. But the finalized notice has not been
- Opinion
- [Reporter's View] Did they have to sell that day?
- by An, Kyung-Jin Nov 16, 2020 06:03am
- The whole world was excited when the news about COVID-19 vaccine developed by Pfizer last week was delivered. This is because Pfizer announced an interim result that the mRNA vaccine, which is being developed jointly with BioNTech in Germany, showed more than 90% prevention effect. The company recruited about 44,000 participants in clinic
